What Should You Know About Tysabri and PML? A Before-and-After Timeline

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Exposure Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Understanding what happens before treatment starts and after symptoms appear can help you make informed decisions. Building on years of medical research and clinical experience, this page provides a clear timeline of PML risk and monitoring.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic medication approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most serious safety alert, to communicate this risk. The boxed warning states that Tysabri increases the risk of PML and that risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating and continuing therapy. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication of the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Postmarketing Data on PML Risk

Clinical trial data have documented PML cases in Tysabri-treated patients. In the clinical development program, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified thousands of adverse event reports associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder, among others (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the range of adverse experiences reported by patients. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance in the brain. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune cells are unable to enter the brain to control the infection. The presence of anti-JCV antibodies indicates prior exposure to the virus and is a key risk factor for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Tysabri-Related PML Cases

From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central concern. The FDA boxed warning and the TOUCH program are designed to inform prescribers and patients of the risk, but questions may arise about whether these measures are sufficient to ensure informed decision-making. Patients who develop PML after Tysabri treatment may face severe outcomes, including death or permanent disability, and may seek legal counsel to evaluate whether they were adequately warned of the risks. Attorney-related considerations for affected patients include the need to document the timeline between Tysabri exposure and the onset of PML symptoms, as well as to assess whether risk factors such as anti-JCV antibody status, treatment duration, and prior immunosuppressant use were properly evaluated and communicated. The timeline between exposure and documented harm is variable. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Postmarketing data suggest that risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may experience progressive neurological deficits, and early diagnosis is critical for management, though outcomes remain poor.

Conclusion: Medical and Legal Collaboration

In summary, Tysabri is associated with a known risk of PML, as detailed in FDA labeling and supported by clinical trial and postmarketing data. The risk is influenced by anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Patients who suffer PML after Tysabri treatment may consider legal options to address potential inadequacies in risk communication. Medical and legal professionals should work together to evaluate individual cases based on documented exposure, risk factors, and clinical outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic medication for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options are available for patients who developed PML after Tysabri?

Patients may seek legal counsel to evaluate whether they were adequately warned of the risks. Documentation of Tysabri exposure, PML diagnosis, and risk factor assessment is crucial. An attorney can help determine if there was a failure to warn or other legal claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.